Shared on 07 Nov 25
Fair value Decreased 1.58%HIMS: Expanding Women's Health Services Will Drive Broader Market Reach
The average analyst price target for Hims & Hers Health has been modestly lowered by approximately $0.75 to $46.67 per share, as analysts trim revenue growth expectations. They also point to intensifying competition and pressure on pricing in the GLP-1 market.
Shared on 19 Sep 25
Fair value Decreased 4.12%Hims & Hers Health faces increased regulatory and legal risks, slowing customer growth, and business momentum concerns, prompting analysts to lower their price target from $49.45 to $47.42. Analyst Commentary Increased regulatory headwinds following new FDA reforms for direct-to-consumer advertising, making customer acquisition and marketing more challenging across digital and broadcast platforms.
Shared on 30 Apr 25
Fair value Decreased 7.68%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 1.48%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 20%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 1.69%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 11 Mar 25
Fair value Decreased 13%AnalystConsensusTarget made no meaningful changes to valuation assumptions.